bpc-157 evidence clinical trials humans human review safety regulatory status Gastric pentadecapeptide body protection compound BPC bpc-157 human clinical trials evidence
Description
Optimal orientation due to the long axis of the myofibers close to the bone and injury area with a lesser number of fibroblasts and a greater amount of collagen fibers was essential for the preservation of myofibrils, so no muscle fiber atrophy was noted
The risk of an adverse event is minimal
No independent comparative study exists to establish this as a clinically validated conclusion
Is Wikipedia's reliance on the collective wisdom of the internet more reliable than the specialized knowledge of Encyclopedia Brittanica's army of paid fact checkers
